Open access

579-C Reinvigoration of progenitor-exhausted CD8 T cells by anti-CTLA-4 contributes to the sustained activity of combination checkpoint blockade
Kevin Wang, Paulina Coutifaris, David Brocks, Sabrina Solis, Nicholas Han, Sasikanth Manne, Evgeny Kiner, Chirag Sachar, Sangeeth George, Patrick Yan, Melanie W Kiner, Amy I Laughlin, Shawn Kothari, Josephine R Giles, Divij Mathew, Rheem Ghinnagow, Cecile Alanio, Ahron Flowers, Wei Xu, Daniel Tenney, Xiaowei Xu, Ravi K Amaravadi, Giorgos C Karakousis, Lynn M Schuchter, Marcus Buggert, E John Wherry, Andy Minn, Jeffrey Weber, Tara Mitchell, Ramin S Herati, Alexander Huang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1804; DOI: 10.1136/jitc-2023-SITC2023.0579-C
579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses
Kartika Padhan, Jung-Min Lee, Elena Giudice, Edward Schrom, Andrea Radtke, Nitasha Gupta, Daniel An, Tzu-Ting Huang, Ronald Germain

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1805; DOI: 10.1136/jitc-2023-SITC2023.0579-D
629-A A safety and feasibility study of the oral live biotherapeutic MRx0518 with hypofractionated preoperative radiation for resectable pancreatic cancer
Vincent Bernard, Sonal Noticewala, Ethan Ludmir, Eric Perez Perez, Ching Wei Tzeng, Shubham Pant, Cullen Taniguchi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1806; DOI: 10.1136/jitc-2023-SITC2023.0629-A
629-B Window of opportunity for durvalumab plus metformin trial in head & neck squamous cell carcinoma (HNSCC)
Ramez Philips, Angela Alnemri, Sruti Tekumalla, Derek Mann, Hushan Yang, Alban Linnenbach, Diana Menezes, Madalina Tuluc, Voichita Bar-Ad, Adam J Luginbuhl, David Cognetti, Ubaldo Martinez-Outschoorn, Jennifer Johnson, Athanassios Argiris, Ramakrishna Mitra, Joseph M Curry

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1807; DOI: 10.1136/jitc-2023-SITC2023.0629-B
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
Tae Min Kim, Nuttapong Ngamphaiboon, Ki Hyeong Lee, Pratibha Desai, Chia-Chi Lin, Jameel Muzaffar, Yin-Hsun Feng, Shang-Yin Wu, Julie Brahmer, Michael Chisamore, Paul D Kassner, Dirk G Brockstedt, Rakesh Kumar Goyal, Nicole Nasrah, William Ho

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1808; DOI: 10.1136/jitc-2023-SITC2023.0629-C
629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and systemic immune response
Andreas N Saltos, Christy Arrowood, Georgia M Beasley, James Ronald, Ghassan El-Haddad, Jhanelle E Gray, Bruna Pellini, Tawee Tanvetyanon, Luiziane Guerra-Guevara, Uzma Khan, Steven Wolf, Lin Gu, Xiaofei Wang, Hong Zheng, Dana Foresman, Xiaoqing Yu, Mark J Cantwell, Scott J Antonia, Amer A Beg, Neal E Ready

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1809; DOI: 10.1136/jitc-2023-SITC2023.0629-D
629-E Randomized trial comparing conventional vs novel treatment planning technique to improve the immune system during lung SBRT
Krishni Wijesooriya, James M Larner, Paul W Read, Timothy N Showalter, Lawrence G Lum, Mark R Conaway, Archana Thakur, Cam Nguyen, David W Lain, Kara Romano, Christopher M McLaughlin, Christopher K Luminais, Einsley Janowski, Donald Muller, Kristin Ward, Sunil Dutta, Jason Sanders, David Cousins, Song Wood, Joe Chen, Ebenezer Asare, Emily Nesbit, Yhana C Chavis, Kristin V Walker

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1810-A1811; DOI: 10.1136/jitc-2023-SITC2023.0629-E
782-B FID-007: nanoencapsulated paclitaxel derived from a novel nano-drug delivery platform
William Witham

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1812; DOI: 10.1136/jitc-2023-SITC2023.0782-B
782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2^nd line anti-PD1/L1 monotherapy in the PIONeeR project
Marcellin Landri, Margot Vasseur, Florence Monville, Vanina Leca, Chafik Hamdad, Margaux Mercadal, Laurent Vanhille, Alboukadel Kassambara, Sebastien Benzekry, Maryannick Le Ray, Marie Roumieux, Richard Malkoun, Arnaud Boyer, Clarisse Audigier-valette, Stephanie Martinez, Hervé Pegliasco, Patrice Ray, Lionel Falchero, Antoine Serre, Nicolas Cloarec, Louisiane Lebas, Stéphane Hominal, Patricia Barré, Sarah Zahi, Ahmed Frikha, Pierre Bory, Lilian Laborde, Julien Mazières, Maurice Pérol, Laurent Greillier, Fabrice Barlesi, Jacques Fieschi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1813; DOI: 10.1136/jitc-2023-SITC2023.0782-C
782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity
Monali Banerjee, Sandip Middya, Ritesh Shrivastava, Anindita Middya, Nagaswamy Mane, Nidhi Rawat, Thanilsana Soram, Debjani Chakraborty, Rajib Ghosh, Rubeena Rais Mansuri, Dharmendra Yadav, Anuj Gautam, Anuj Singh, Kavita Puniya, David Pryde, Sourav Basu, Fabiane Sonego, Gaelle Martin, Perrine Martin-Jeantet, Angela Pappalardo, Kader Thiam, Ciara Kelly, Arjun Surya

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 2) A1814; DOI: 10.1136/jitc-2023-SITC2023.0782-D

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages